Clinical Trial Update: A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients [Phase 3]

View source ↗

Summary

This document summarizes the long-term safety and tolerability extension of bapineuzumab in patients with Alzheimer's disease in a Phase 3 program, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Bapineuzumab (bapineuzumab)

Snippet

Sponsor: Pfizer | Conditions: Alzheimer Disease | Phase 3 | Status: TERMINATED | Results posted: 2016-01-01